Remix Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on the research and development of innovative small molecule therapies that reprogram RNA processing to address various diseases. Founded in 2018, the company utilizes a biology platform to identify and prioritize therapeutic targets within RNA processing, aiming to tackle previously undruggable disease drivers. Its REMseq platform assists in validating these targets and optimizing chemical compounds for potential treatments. By analyzing patterns in RNA processing, Remix Therapeutics seeks to modulate gene expression, thereby enabling healthcare providers to correct or enhance genetic messages at their source, ultimately aiming to provide new approaches for treating diseases.
Plexium, Inc. is a biotechnology company based in San Diego, California, established in 2017. The company specializes in drug development, focusing on the identification of small molecules that modulate E3 ligases for therapeutic applications in cancer and neurodegenerative diseases. Plexium employs a DNA-encoded library platform to conduct high-throughput screening, utilizing cell-based assays to discover molecular glues that can alter E3 ligase substrate recognition, thereby inducing, inhibiting, or modulating protein degradation. This innovative approach allows Plexium to selectively target various cancers, including small cell lung and breast tumors, while also exploring mechanisms to enhance immune responses through E3 ligase modulation.
Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.
Eikon Therapeutics is a biopharmaceutical company focused on developing innovative treatments for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company utilizes advanced super-resolution microscopy technology to conduct live-cell and single-molecule imaging. This cutting-edge approach allows for real-time, molecular-resolution measurements of protein movement within living cells, enabling the identification of previously intractable drug targets. By directly measuring the interactions between chemical compounds and individual proteins in a cellular environment, Eikon Therapeutics aims to unlock new avenues for drug discovery and address complex health challenges.
Obsidian Therapeutics develops innovative cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Founded in 2015 and based in Cambridge, Massachusetts, the company focuses on creating next-generation therapies that utilize pharmacologic operating systems to provide precise control over protein activity within cells. This technology allows for the development of adoptive cell therapies with advanced functionalities that can be managed by physicians using simple, safe, and orally active medications. By offering improved control over treatment, Obsidian Therapeutics aims to provide better outcomes for patients compared to existing cell therapy options.
Effector Therapeutics is a biotechnology company based in San Diego, California, that specializes in the development of small molecule drugs aimed at treating cancer and other serious diseases. Founded in 2012, the company focuses on creating selective translation regulators that target the regulation of protein synthesis, a critical process in tumor growth and survival. By selectively blocking dysregulated translation, Effector Therapeutics aims to inhibit cancer cell proliferation while providing a potent and targeted therapeutic approach. This innovative strategy positions the company to potentially deliver new and effective treatments to patients facing challenging health conditions.
Atavistik Bio is a pre-clinical biotechnology company pioneering the identification of metabolite-protein interactions that have the potential to lead to the discovery and development of first-in-class drug candidates powered by distinct allosteric control mechanisms.
Surrozen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in developing targeted regenerative antibodies aimed at repairing tissues and organs affected by serious diseases. The company utilizes antibody platforms that act as Wnt and R-spondin mimetics to stimulate cell and organ-specific tissue regeneration. Its key programs include SZN-043, which is designed to promote hepatocyte regeneration in both acute and chronic liver diseases, and SZN-1326, an intestine-specific Wnt-mimetic intended to repair diseased epithelial tissue for patients suffering from inflammatory bowel disease. Surrozen was incorporated in 2015 and is focused on harnessing the body's self-renewal capabilities through precise control of the Wnt signaling pathway.
Hexagon Bio, Inc. is a biotechnology company based in Menlo Park, California, that specializes in mining genomic data from fungal genomes to develop targeted small molecule therapeutics for diseases with unmet medical needs. Founded in 2016, the company leverages a proprietary platform that integrates data science, synthetic biology, and automation to discover and engineer novel drugs. By focusing on evolutionarily refined molecules and their corresponding protein targets, Hexagon Bio aims to identify and develop new medicines from the global metagenome, ultimately striving to enhance patient outcomes through innovative therapeutic solutions.
Neurona Therapeutics Inc. develops cell-based therapies for the treatment of neurological disorders. The company develop therapeutic compositions of specific nerve cells for targeted delivery into the injured nervous system. The company was incorporated in 2008 and is based in South San Francisco, California.
Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, focused on developing cell-permeable macrocyclic peptide therapeutics. Founded in 2012 by Professors Matt Jacobson and Scott Lokey, the company utilizes proprietary computational design algorithms and innovative synthetic chemistry to create macrocycles targeting significant clinical challenges. Their approach involves an iterative design process that leverages large virtual libraries of diverse macrocycle scaffolds, selected for their permeability. Circle Pharma aims to address unmet clinical needs, particularly in the treatment of cancer, by focusing on intracellular protein-protein interactions through its novel macrocycle therapies, which can be delivered via multiple routes, including oral administration. The company's work is intended to enable healthcare professionals to advance internal development efforts in this critical area of medicine.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Synthekine Inc. is a biotechnology company focused on the development of engineered cytokine therapies and immunotherapies aimed at treating cancer and autoimmune disorders. Founded in 2018 and based in Menlo Park, California, Synthekine utilizes innovative platform technologies, including engineered partial agonists and orthogonal cell therapies, to create differentiated therapeutics. Its product pipeline features STK-009, an orthogonal ligand, and SYNCAR-001, a CAR-T therapy modified with orthogonal receptors. Additionally, the company is advancing STK-012, a partial agonist of IL-2, alongside Synthekines, which are designed to enhance signaling activities by combining cytokine receptors without relying on wild-type cytokines. Synthekine's approach is informed by immunological insights to ensure that its treatments are both safe and effective, with promising preclinical results indicating potential for improved efficacy and tolerability.
Eikon Therapeutics is a biopharmaceutical company focused on developing innovative treatments for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company utilizes advanced super-resolution microscopy technology to conduct live-cell and single-molecule imaging. This cutting-edge approach allows for real-time, molecular-resolution measurements of protein movement within living cells, enabling the identification of previously intractable drug targets. By directly measuring the interactions between chemical compounds and individual proteins in a cellular environment, Eikon Therapeutics aims to unlock new avenues for drug discovery and address complex health challenges.
Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.
Plexium, Inc. is a biotechnology company based in San Diego, California, established in 2017. The company specializes in drug development, focusing on the identification of small molecules that modulate E3 ligases for therapeutic applications in cancer and neurodegenerative diseases. Plexium employs a DNA-encoded library platform to conduct high-throughput screening, utilizing cell-based assays to discover molecular glues that can alter E3 ligase substrate recognition, thereby inducing, inhibiting, or modulating protein degradation. This innovative approach allows Plexium to selectively target various cancers, including small cell lung and breast tumors, while also exploring mechanisms to enhance immune responses through E3 ligase modulation.
Remix Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on the research and development of innovative small molecule therapies that reprogram RNA processing to address various diseases. Founded in 2018, the company utilizes a biology platform to identify and prioritize therapeutic targets within RNA processing, aiming to tackle previously undruggable disease drivers. Its REMseq platform assists in validating these targets and optimizing chemical compounds for potential treatments. By analyzing patterns in RNA processing, Remix Therapeutics seeks to modulate gene expression, thereby enabling healthcare providers to correct or enhance genetic messages at their source, ultimately aiming to provide new approaches for treating diseases.
A2 Biotherapeutics is an early-stage biotechnology company located in Southern California that develops novel medicines for serious illnesses. We utilize an advanced targeting technology platform to increase the effectiveness of the body’s natural immune defenses.
Carmot Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapies for metabolic diseases, including obesity and diabetes. Founded in 2008 and based in Berkeley, California, with an additional office in San Francisco, the company employs a unique drug discovery approach known as Chemotype Evolution to explore innovative chemistry and biology. Carmot's portfolio includes several drug candidates aimed at treating metabolic disorders and oncology, such as CT-388, a dual GLP-1/GIP receptor agonist designed for obesity and type 2 diabetes, CT-996, an oral small molecule GLP-1 receptor agonist for the same conditions, and CT-868, another dual GLP-1/GIP receptor agonist specifically for type 1 diabetes patients who are overweight or obese. Through these efforts, Carmot Therapeutics seeks to provide effective treatments that improve the quality of life for individuals affected by these diseases.
Synthekine Inc. is a biotechnology company focused on the development of engineered cytokine therapies and immunotherapies aimed at treating cancer and autoimmune disorders. Founded in 2018 and based in Menlo Park, California, Synthekine utilizes innovative platform technologies, including engineered partial agonists and orthogonal cell therapies, to create differentiated therapeutics. Its product pipeline features STK-009, an orthogonal ligand, and SYNCAR-001, a CAR-T therapy modified with orthogonal receptors. Additionally, the company is advancing STK-012, a partial agonist of IL-2, alongside Synthekines, which are designed to enhance signaling activities by combining cytokine receptors without relying on wild-type cytokines. Synthekine's approach is informed by immunological insights to ensure that its treatments are both safe and effective, with promising preclinical results indicating potential for improved efficacy and tolerability.
Hexagon Bio, Inc. is a biotechnology company based in Menlo Park, California, that specializes in mining genomic data from fungal genomes to develop targeted small molecule therapeutics for diseases with unmet medical needs. Founded in 2016, the company leverages a proprietary platform that integrates data science, synthetic biology, and automation to discover and engineer novel drugs. By focusing on evolutionarily refined molecules and their corresponding protein targets, Hexagon Bio aims to identify and develop new medicines from the global metagenome, ultimately striving to enhance patient outcomes through innovative therapeutic solutions.
Escient Pharmaceuticals, Inc., a biotechnology company, develops and manufactures G protein-coupled receptor (GPCR)-targeted drugs for treating neuro-immuno-inflammatory and autoreactive diseases. The company focuses on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs) for neuro-immuno-inflammatory and autoreactive diseases. Escient Pharmaceuticals, Inc. was formerly known as Mas Therapeutics, Inc. The company was founded in 2017 and is based in San Diego, California.
Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.
Nura Bio, Inc., a biopharmaceutical company, discovers and develops neuroprotective drugs that prevent axon loss after acute injury/chronic degenerative disease. It offers SARM1, an axon-intrinsic metabolic sensor and regulator with putative immune function, playing a central role in axonal degeneration; and develops small molecule inhibitors of SARM1 for the treatment of peripheral, central, and ocular nervous system disorders. Nura Bio, Inc. was formerly known as Proneurotech, Inc. and changed its name to Nura Bio, Inc. in February 2020. The company was incorporated in 2017 and is based in South San Francisco, California.
Accent Therapeutics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing small molecule therapies for oncology through the innovative field of epitranscriptomics. Founded in 2017, the company explores post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting RNA-modifying proteins associated with cancer, Accent Therapeutics aims to translate advanced scientific research into effective treatments for patients, ultimately providing new therapeutic options in the fight against cancer.
Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, focused on developing cell-permeable macrocyclic peptide therapeutics. Founded in 2012 by Professors Matt Jacobson and Scott Lokey, the company utilizes proprietary computational design algorithms and innovative synthetic chemistry to create macrocycles targeting significant clinical challenges. Their approach involves an iterative design process that leverages large virtual libraries of diverse macrocycle scaffolds, selected for their permeability. Circle Pharma aims to address unmet clinical needs, particularly in the treatment of cancer, by focusing on intracellular protein-protein interactions through its novel macrocycle therapies, which can be delivered via multiple routes, including oral administration. The company's work is intended to enable healthcare professionals to advance internal development efforts in this critical area of medicine.
Nurix Therapeutics is a biopharmaceutical company dedicated to the discovery and development of small molecule therapies aimed at treating cancer and immune disorders. The company focuses on innovative approaches to modulate cellular protein levels, utilizing its expertise in the ubiquitin-proteasome system. Its lead preclinical candidates include NX-2127, an orally available Bruton’s tyrosine kinase (BTK) degrader targeting relapsed or refractory B-cell malignancies, and NX-1607, a Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology applications. Nurix also offers DELigase, a discovery platform that identifies and advances novel drug candidates by targeting E3 ligases, which play a crucial role in protein regulation. Founded in 2009 and based in San Francisco, the company has established strategic collaborations with major pharmaceutical firms, enhancing its potential in the competitive biopharmaceutical landscape.
Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.
A2 Biotherapeutics is an early-stage biotechnology company located in Southern California that develops novel medicines for serious illnesses. We utilize an advanced targeting technology platform to increase the effectiveness of the body’s natural immune defenses.
Plexium, Inc. is a biotechnology company based in San Diego, California, established in 2017. The company specializes in drug development, focusing on the identification of small molecules that modulate E3 ligases for therapeutic applications in cancer and neurodegenerative diseases. Plexium employs a DNA-encoded library platform to conduct high-throughput screening, utilizing cell-based assays to discover molecular glues that can alter E3 ligase substrate recognition, thereby inducing, inhibiting, or modulating protein degradation. This innovative approach allows Plexium to selectively target various cancers, including small cell lung and breast tumors, while also exploring mechanisms to enhance immune responses through E3 ligase modulation.
Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatment. Founded in 2014 and based in South San Francisco, California, the company is advancing several product candidates, including ORIC-101, a small molecule antagonist of the glucocorticoid receptor associated with resistance to various cancer therapies in solid tumors. Another key candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, which plays a significant role in resistance to chemotherapy and immunotherapy regimens. In addition to these, ORIC is working on multiple precision medicines aimed at addressing other cancer resistance mechanisms. The company's founders, Charles Sawyers and Scott Lowe, are recognized for their contributions to identifying novel cancer targets that have led to innovative treatment options.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the discovery and development of oral small molecule therapies for oncology and inflammatory diseases. The company is focused on addressing significant unmet medical needs through its proprietary discovery engine. Its lead oncology candidate, FLX475, is a C-C motif chemokine receptor 4 antagonist currently undergoing Phase 2 clinical trials, both as a monotherapy and in combination with pembrolizumab, for various tumor types. Additionally, RAPT's lead inflammation drug candidate, RPT193, aims to selectively inhibit the migration of type 2 T helper cells into allergically inflamed tissues. The company is also exploring other potential targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are in the discovery phase. Founded in 2015, RAPT Therapeutics was previously known as FLX Bio, Inc. before its name change in May 2019.
Surrozen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in developing targeted regenerative antibodies aimed at repairing tissues and organs affected by serious diseases. The company utilizes antibody platforms that act as Wnt and R-spondin mimetics to stimulate cell and organ-specific tissue regeneration. Its key programs include SZN-043, which is designed to promote hepatocyte regeneration in both acute and chronic liver diseases, and SZN-1326, an intestine-specific Wnt-mimetic intended to repair diseased epithelial tissue for patients suffering from inflammatory bowel disease. Surrozen was incorporated in 2015 and is focused on harnessing the body's self-renewal capabilities through precise control of the Wnt signaling pathway.
Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, focused on developing innovative medicines for cancer and other serious conditions. The company's lead candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma. Additionally, Peloton is exploring PT2977 in various other indications, including von Hippel-Lindau disease-associated renal cell carcinoma and glioblastoma multiforme, as well as in combination therapies for metastatic renal cell carcinoma. Furthermore, Peloton is developing PT2567, another oral HIF-2a inhibitor in preclinical stages aimed at non-oncology applications, notably pulmonary arterial hypertension. Founded in 2010 and initially known as Damascus Pharmaceutics, Peloton Therapeutics has formed strong partnerships with academic institutions and secured funding from organizations like the Cancer Prevention Research Institute of Texas, positioning itself as a key player in the biotech sector.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Remix Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on the research and development of innovative small molecule therapies that reprogram RNA processing to address various diseases. Founded in 2018, the company utilizes a biology platform to identify and prioritize therapeutic targets within RNA processing, aiming to tackle previously undruggable disease drivers. Its REMseq platform assists in validating these targets and optimizing chemical compounds for potential treatments. By analyzing patterns in RNA processing, Remix Therapeutics seeks to modulate gene expression, thereby enabling healthcare providers to correct or enhance genetic messages at their source, ultimately aiming to provide new approaches for treating diseases.
Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.
Accent Therapeutics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing small molecule therapies for oncology through the innovative field of epitranscriptomics. Founded in 2017, the company explores post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting RNA-modifying proteins associated with cancer, Accent Therapeutics aims to translate advanced scientific research into effective treatments for patients, ultimately providing new therapeutic options in the fight against cancer.
Escient Pharmaceuticals, Inc., a biotechnology company, develops and manufactures G protein-coupled receptor (GPCR)-targeted drugs for treating neuro-immuno-inflammatory and autoreactive diseases. The company focuses on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs) for neuro-immuno-inflammatory and autoreactive diseases. Escient Pharmaceuticals, Inc. was formerly known as Mas Therapeutics, Inc. The company was founded in 2017 and is based in San Diego, California.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.
Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatment. Founded in 2014 and based in South San Francisco, California, the company is advancing several product candidates, including ORIC-101, a small molecule antagonist of the glucocorticoid receptor associated with resistance to various cancer therapies in solid tumors. Another key candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, which plays a significant role in resistance to chemotherapy and immunotherapy regimens. In addition to these, ORIC is working on multiple precision medicines aimed at addressing other cancer resistance mechanisms. The company's founders, Charles Sawyers and Scott Lowe, are recognized for their contributions to identifying novel cancer targets that have led to innovative treatment options.
ProNeurotech is a developer of neuroprotective drugs that prevent axon loss after acute injury or chronic degenerative disease. The company's business includes research in biochemistry, genetics, neurology and synthetic chemistry that drive the synthesis of the cardinal metabolite, nicotinamide adenine dinucleotide, enabling patients with neurodegenerative diseases to have access to treatment of neurologic and ocular diseases.
Carmot Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapies for metabolic diseases, including obesity and diabetes. Founded in 2008 and based in Berkeley, California, with an additional office in San Francisco, the company employs a unique drug discovery approach known as Chemotype Evolution to explore innovative chemistry and biology. Carmot's portfolio includes several drug candidates aimed at treating metabolic disorders and oncology, such as CT-388, a dual GLP-1/GIP receptor agonist designed for obesity and type 2 diabetes, CT-996, an oral small molecule GLP-1 receptor agonist for the same conditions, and CT-868, another dual GLP-1/GIP receptor agonist specifically for type 1 diabetes patients who are overweight or obese. Through these efforts, Carmot Therapeutics seeks to provide effective treatments that improve the quality of life for individuals affected by these diseases.
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the discovery and development of oral small molecule therapies for oncology and inflammatory diseases. The company is focused on addressing significant unmet medical needs through its proprietary discovery engine. Its lead oncology candidate, FLX475, is a C-C motif chemokine receptor 4 antagonist currently undergoing Phase 2 clinical trials, both as a monotherapy and in combination with pembrolizumab, for various tumor types. Additionally, RAPT's lead inflammation drug candidate, RPT193, aims to selectively inhibit the migration of type 2 T helper cells into allergically inflamed tissues. The company is also exploring other potential targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are in the discovery phase. Founded in 2015, RAPT Therapeutics was previously known as FLX Bio, Inc. before its name change in May 2019.
Arcus Biosciences is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies through insights in immunology. Founded in 2015 by experienced researchers from the biotechnology sector, the company is advancing a pipeline that includes several promising candidates. Notably, it is developing AB928, a dual A2a/A2b adenosine receptor antagonist, and Zimberelimab, an anti-PD-1 monoclonal antibody, both currently in clinical trials. Additionally, Arcus is working on AB154, an anti-TIGIT monoclonal antibody, and AB680, a small-molecule CD73 inhibitor, targeting various cancer types such as non-small cell lung cancer and pancreatic cancer. The company has established partnerships with organizations like Strata Oncology and AstraZeneca to enhance its research efforts and expand its clinical trials. By focusing on the ATP-adenosine pathway, which plays a crucial role in tumor immunosuppression, Arcus aims to create and optimize differentiated immuno-oncology therapies for patients.
Exonics Therapeutics, Inc. develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of duchenne muscular dystrophy mutations. The company was founded in 2017 and is headquartered in Boston, Massachusetts with additional office in Dallas, Texas. As of July 16, 2019, Exonics Therapeutics, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated.
Gritstone Bio is a biotechnology company focused on developing personalized cancer immunotherapies aimed at treating various cancer types and infectious diseases. The company is advancing its lead product candidates, GRANITE and SLATE, both of which are in Phase I/II clinical trials. GRANITE targets solid tumors, including metastatic non-small cell lung cancer and gastroesophageal cancer, while SLATE serves as an off-the-shelf immunotherapy for common solid tumors and mutation-positive cancers. Gritstone is committed to identifying therapeutic neo-antigens from individual patients' tumors to create novel treatments, leveraging the expertise of its scientific founders and management team. Founded in 2015 and headquartered in Emeryville, California, the company is also engaged in strategic collaborations to enhance its research and development efforts.
Effector Therapeutics is a biotechnology company based in San Diego, California, that specializes in the development of small molecule drugs aimed at treating cancer and other serious diseases. Founded in 2012, the company focuses on creating selective translation regulators that target the regulation of protein synthesis, a critical process in tumor growth and survival. By selectively blocking dysregulated translation, Effector Therapeutics aims to inhibit cancer cell proliferation while providing a potent and targeted therapeutic approach. This innovative strategy positions the company to potentially deliver new and effective treatments to patients facing challenging health conditions.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.
Surrozen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in developing targeted regenerative antibodies aimed at repairing tissues and organs affected by serious diseases. The company utilizes antibody platforms that act as Wnt and R-spondin mimetics to stimulate cell and organ-specific tissue regeneration. Its key programs include SZN-043, which is designed to promote hepatocyte regeneration in both acute and chronic liver diseases, and SZN-1326, an intestine-specific Wnt-mimetic intended to repair diseased epithelial tissue for patients suffering from inflammatory bowel disease. Surrozen was incorporated in 2015 and is focused on harnessing the body's self-renewal capabilities through precise control of the Wnt signaling pathway.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.
Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, focused on developing innovative medicines for cancer and other serious conditions. The company's lead candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma. Additionally, Peloton is exploring PT2977 in various other indications, including von Hippel-Lindau disease-associated renal cell carcinoma and glioblastoma multiforme, as well as in combination therapies for metastatic renal cell carcinoma. Furthermore, Peloton is developing PT2567, another oral HIF-2a inhibitor in preclinical stages aimed at non-oncology applications, notably pulmonary arterial hypertension. Founded in 2010 and initially known as Damascus Pharmaceutics, Peloton Therapeutics has formed strong partnerships with academic institutions and secured funding from organizations like the Cancer Prevention Research Institute of Texas, positioning itself as a key player in the biotech sector.
Arcus Biosciences is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies through insights in immunology. Founded in 2015 by experienced researchers from the biotechnology sector, the company is advancing a pipeline that includes several promising candidates. Notably, it is developing AB928, a dual A2a/A2b adenosine receptor antagonist, and Zimberelimab, an anti-PD-1 monoclonal antibody, both currently in clinical trials. Additionally, Arcus is working on AB154, an anti-TIGIT monoclonal antibody, and AB680, a small-molecule CD73 inhibitor, targeting various cancer types such as non-small cell lung cancer and pancreatic cancer. The company has established partnerships with organizations like Strata Oncology and AstraZeneca to enhance its research efforts and expand its clinical trials. By focusing on the ATP-adenosine pathway, which plays a crucial role in tumor immunosuppression, Arcus aims to create and optimize differentiated immuno-oncology therapies for patients.
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the discovery and development of oral small molecule therapies for oncology and inflammatory diseases. The company is focused on addressing significant unmet medical needs through its proprietary discovery engine. Its lead oncology candidate, FLX475, is a C-C motif chemokine receptor 4 antagonist currently undergoing Phase 2 clinical trials, both as a monotherapy and in combination with pembrolizumab, for various tumor types. Additionally, RAPT's lead inflammation drug candidate, RPT193, aims to selectively inhibit the migration of type 2 T helper cells into allergically inflamed tissues. The company is also exploring other potential targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are in the discovery phase. Founded in 2015, RAPT Therapeutics was previously known as FLX Bio, Inc. before its name change in May 2019.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Effector Therapeutics is a biotechnology company based in San Diego, California, that specializes in the development of small molecule drugs aimed at treating cancer and other serious diseases. Founded in 2012, the company focuses on creating selective translation regulators that target the regulation of protein synthesis, a critical process in tumor growth and survival. By selectively blocking dysregulated translation, Effector Therapeutics aims to inhibit cancer cell proliferation while providing a potent and targeted therapeutic approach. This innovative strategy positions the company to potentially deliver new and effective treatments to patients facing challenging health conditions.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatment. Founded in 2014 and based in South San Francisco, California, the company is advancing several product candidates, including ORIC-101, a small molecule antagonist of the glucocorticoid receptor associated with resistance to various cancer therapies in solid tumors. Another key candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, which plays a significant role in resistance to chemotherapy and immunotherapy regimens. In addition to these, ORIC is working on multiple precision medicines aimed at addressing other cancer resistance mechanisms. The company's founders, Charles Sawyers and Scott Lowe, are recognized for their contributions to identifying novel cancer targets that have led to innovative treatment options.
Neurona Therapeutics Inc. develops cell-based therapies for the treatment of neurological disorders. The company develop therapeutic compositions of specific nerve cells for targeted delivery into the injured nervous system. The company was incorporated in 2008 and is based in South San Francisco, California.
Gritstone Bio is a biotechnology company focused on developing personalized cancer immunotherapies aimed at treating various cancer types and infectious diseases. The company is advancing its lead product candidates, GRANITE and SLATE, both of which are in Phase I/II clinical trials. GRANITE targets solid tumors, including metastatic non-small cell lung cancer and gastroesophageal cancer, while SLATE serves as an off-the-shelf immunotherapy for common solid tumors and mutation-positive cancers. Gritstone is committed to identifying therapeutic neo-antigens from individual patients' tumors to create novel treatments, leveraging the expertise of its scientific founders and management team. Founded in 2015 and headquartered in Emeryville, California, the company is also engaged in strategic collaborations to enhance its research and development efforts.
Arcus Biosciences is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies through insights in immunology. Founded in 2015 by experienced researchers from the biotechnology sector, the company is advancing a pipeline that includes several promising candidates. Notably, it is developing AB928, a dual A2a/A2b adenosine receptor antagonist, and Zimberelimab, an anti-PD-1 monoclonal antibody, both currently in clinical trials. Additionally, Arcus is working on AB154, an anti-TIGIT monoclonal antibody, and AB680, a small-molecule CD73 inhibitor, targeting various cancer types such as non-small cell lung cancer and pancreatic cancer. The company has established partnerships with organizations like Strata Oncology and AstraZeneca to enhance its research efforts and expand its clinical trials. By focusing on the ATP-adenosine pathway, which plays a crucial role in tumor immunosuppression, Arcus aims to create and optimize differentiated immuno-oncology therapies for patients.
NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for various diseases, including cardio-metabolic, liver, oncologic, and ophthalmic conditions. The company is advancing several product candidates, such as Aldafermin, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH), and NGM313, an antibody in Phase 1b trials aimed at treating type 2 diabetes and NASH. Other notable candidates include NGM395 for metabolic syndrome, NGM120 targeting cancer anorexia/cachexia syndrome, NGM217 to enhance insulin production in diabetes patients, and NGM621 for addressing dry age-related macular degeneration. Founded in 2007 and headquartered in South San Francisco, NGM Biopharmaceuticals is committed to leveraging insights from human clinical and genetic studies to develop transformative therapies, particularly focusing on the gastrointestinal endocrine system and its role in metabolic diseases. The company collaborates with Merck Sharp & Dohme Corp for research and product development initiatives.
Flexus is a privately-held biopharmaceutical company focused on the creation, development, and commercialization of novel anti-cancer therapeutics through an innovative application of unexploited insights in immunology. Founded in 2013, Flexus is headquartered in San Carlos, California.
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatment. Founded in 2014 and based in South San Francisco, California, the company is advancing several product candidates, including ORIC-101, a small molecule antagonist of the glucocorticoid receptor associated with resistance to various cancer therapies in solid tumors. Another key candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, which plays a significant role in resistance to chemotherapy and immunotherapy regimens. In addition to these, ORIC is working on multiple precision medicines aimed at addressing other cancer resistance mechanisms. The company's founders, Charles Sawyers and Scott Lowe, are recognized for their contributions to identifying novel cancer targets that have led to innovative treatment options.
Nurix Therapeutics is a biopharmaceutical company dedicated to the discovery and development of small molecule therapies aimed at treating cancer and immune disorders. The company focuses on innovative approaches to modulate cellular protein levels, utilizing its expertise in the ubiquitin-proteasome system. Its lead preclinical candidates include NX-2127, an orally available Bruton’s tyrosine kinase (BTK) degrader targeting relapsed or refractory B-cell malignancies, and NX-1607, a Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology applications. Nurix also offers DELigase, a discovery platform that identifies and advances novel drug candidates by targeting E3 ligases, which play a crucial role in protein regulation. Founded in 2009 and based in San Francisco, the company has established strategic collaborations with major pharmaceutical firms, enhancing its potential in the competitive biopharmaceutical landscape.
Igenica, Inc. is a biotherapeutic company based in Burlingame, California, specializing in the discovery and development of antibodies and antibody-drug conjugates for cancer treatment. The company is dedicated to advancing immunotherapies and functional antibodies that target tumors, as well as creating antibody-drug conjugates. Igenica's key products include IGN523, a humanized monoclonal antibody aimed at various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, which targets immune checkpoints in the tumor microenvironment. Founded in 2008, Igenica operates with a strategic oncology research agreement with MedImmune and is backed by prominent life science investors. The leadership team at Igenica has significant experience in antibody drug discovery and has contributed to the development of multiple approved antibody therapeutic products.
Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence
Seragon Pharmaceuticals, Inc., headquartered in Irvine, California, is a research-based biopharmaceutical company dedicated to improving human and animal health through innovative science. Seragon Pharmaceuticals is committed to applying cutting-edge scientific and technological advancements to the fields of metabolism, gene therapy and bioinformatics. From the research end to consumer products and clinical applications, Seragon strives to bring people access to the most significant breakthroughs in medicine. For more information, please visit www.seragon.com
Nurix Therapeutics is a biopharmaceutical company dedicated to the discovery and development of small molecule therapies aimed at treating cancer and immune disorders. The company focuses on innovative approaches to modulate cellular protein levels, utilizing its expertise in the ubiquitin-proteasome system. Its lead preclinical candidates include NX-2127, an orally available Bruton’s tyrosine kinase (BTK) degrader targeting relapsed or refractory B-cell malignancies, and NX-1607, a Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology applications. Nurix also offers DELigase, a discovery platform that identifies and advances novel drug candidates by targeting E3 ligases, which play a crucial role in protein regulation. Founded in 2009 and based in San Francisco, the company has established strategic collaborations with major pharmaceutical firms, enhancing its potential in the competitive biopharmaceutical landscape.
Aragon Pharmaceuticals is a discovery-stage small molecule company dedicated to developing therapeutics for hormone-resistant cancers, particularly focusing on prostate and breast cancer. The company specializes in anti-endocrine therapies that target the biology of these cancers. Its research emphasizes nuclear receptor biology, medicinal chemistry, and drug discovery, with the goal of identifying and developing selective androgen receptor degraders for prostate cancer and selective estrogen receptor degraders for estrogen-sensitive breast cancer.
Carmot Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapies for metabolic diseases, including obesity and diabetes. Founded in 2008 and based in Berkeley, California, with an additional office in San Francisco, the company employs a unique drug discovery approach known as Chemotype Evolution to explore innovative chemistry and biology. Carmot's portfolio includes several drug candidates aimed at treating metabolic disorders and oncology, such as CT-388, a dual GLP-1/GIP receptor agonist designed for obesity and type 2 diabetes, CT-996, an oral small molecule GLP-1 receptor agonist for the same conditions, and CT-868, another dual GLP-1/GIP receptor agonist specifically for type 1 diabetes patients who are overweight or obese. Through these efforts, Carmot Therapeutics seeks to provide effective treatments that improve the quality of life for individuals affected by these diseases.
Igenica, Inc. is a biotherapeutic company based in Burlingame, California, specializing in the discovery and development of antibodies and antibody-drug conjugates for cancer treatment. The company is dedicated to advancing immunotherapies and functional antibodies that target tumors, as well as creating antibody-drug conjugates. Igenica's key products include IGN523, a humanized monoclonal antibody aimed at various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, which targets immune checkpoints in the tumor microenvironment. Founded in 2008, Igenica operates with a strategic oncology research agreement with MedImmune and is backed by prominent life science investors. The leadership team at Igenica has significant experience in antibody drug discovery and has contributed to the development of multiple approved antibody therapeutic products.
Nurix Therapeutics is a biopharmaceutical company dedicated to the discovery and development of small molecule therapies aimed at treating cancer and immune disorders. The company focuses on innovative approaches to modulate cellular protein levels, utilizing its expertise in the ubiquitin-proteasome system. Its lead preclinical candidates include NX-2127, an orally available Bruton’s tyrosine kinase (BTK) degrader targeting relapsed or refractory B-cell malignancies, and NX-1607, a Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology applications. Nurix also offers DELigase, a discovery platform that identifies and advances novel drug candidates by targeting E3 ligases, which play a crucial role in protein regulation. Founded in 2009 and based in San Francisco, the company has established strategic collaborations with major pharmaceutical firms, enhancing its potential in the competitive biopharmaceutical landscape.
NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for various diseases, including cardio-metabolic, liver, oncologic, and ophthalmic conditions. The company is advancing several product candidates, such as Aldafermin, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH), and NGM313, an antibody in Phase 1b trials aimed at treating type 2 diabetes and NASH. Other notable candidates include NGM395 for metabolic syndrome, NGM120 targeting cancer anorexia/cachexia syndrome, NGM217 to enhance insulin production in diabetes patients, and NGM621 for addressing dry age-related macular degeneration. Founded in 2007 and headquartered in South San Francisco, NGM Biopharmaceuticals is committed to leveraging insights from human clinical and genetic studies to develop transformative therapies, particularly focusing on the gastrointestinal endocrine system and its role in metabolic diseases. The company collaborates with Merck Sharp & Dohme Corp for research and product development initiatives.
Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, focused on developing innovative medicines for cancer and other serious conditions. The company's lead candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma. Additionally, Peloton is exploring PT2977 in various other indications, including von Hippel-Lindau disease-associated renal cell carcinoma and glioblastoma multiforme, as well as in combination therapies for metastatic renal cell carcinoma. Furthermore, Peloton is developing PT2567, another oral HIF-2a inhibitor in preclinical stages aimed at non-oncology applications, notably pulmonary arterial hypertension. Founded in 2010 and initially known as Damascus Pharmaceutics, Peloton Therapeutics has formed strong partnerships with academic institutions and secured funding from organizations like the Cancer Prevention Research Institute of Texas, positioning itself as a key player in the biotech sector.
Cyterix Pharmaceuticals, Inc. is a cancer therapeutics company focused on the discovery and development of small molecule oncology prodrugs. Founded in 2010 and based in San Francisco, California, the company employs a proprietary OncoCYP prodrug discovery approach to create novel classes of anticancer therapies. This technology platform allows for the design of prodrugs that are selectively activated by cytochrome P450 enzymes, which are significantly over-expressed in various solid tumors and hematologic cancers, while remaining inactive in normal tissues. By enhancing safety and efficacy compared to traditional cancer treatments, Cyterix aims to improve therapeutic outcomes for patients with cancer.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.
Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence
Igenica, Inc. is a biotherapeutic company based in Burlingame, California, specializing in the discovery and development of antibodies and antibody-drug conjugates for cancer treatment. The company is dedicated to advancing immunotherapies and functional antibodies that target tumors, as well as creating antibody-drug conjugates. Igenica's key products include IGN523, a humanized monoclonal antibody aimed at various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, which targets immune checkpoints in the tumor microenvironment. Founded in 2008, Igenica operates with a strategic oncology research agreement with MedImmune and is backed by prominent life science investors. The leadership team at Igenica has significant experience in antibody drug discovery and has contributed to the development of multiple approved antibody therapeutic products.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.
Aragon Pharmaceuticals is a discovery-stage small molecule company dedicated to developing therapeutics for hormone-resistant cancers, particularly focusing on prostate and breast cancer. The company specializes in anti-endocrine therapies that target the biology of these cancers. Its research emphasizes nuclear receptor biology, medicinal chemistry, and drug discovery, with the goal of identifying and developing selective androgen receptor degraders for prostate cancer and selective estrogen receptor degraders for estrogen-sensitive breast cancer.
Carmot Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapies for metabolic diseases, including obesity and diabetes. Founded in 2008 and based in Berkeley, California, with an additional office in San Francisco, the company employs a unique drug discovery approach known as Chemotype Evolution to explore innovative chemistry and biology. Carmot's portfolio includes several drug candidates aimed at treating metabolic disorders and oncology, such as CT-388, a dual GLP-1/GIP receptor agonist designed for obesity and type 2 diabetes, CT-996, an oral small molecule GLP-1 receptor agonist for the same conditions, and CT-868, another dual GLP-1/GIP receptor agonist specifically for type 1 diabetes patients who are overweight or obese. Through these efforts, Carmot Therapeutics seeks to provide effective treatments that improve the quality of life for individuals affected by these diseases.
NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for various diseases, including cardio-metabolic, liver, oncologic, and ophthalmic conditions. The company is advancing several product candidates, such as Aldafermin, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH), and NGM313, an antibody in Phase 1b trials aimed at treating type 2 diabetes and NASH. Other notable candidates include NGM395 for metabolic syndrome, NGM120 targeting cancer anorexia/cachexia syndrome, NGM217 to enhance insulin production in diabetes patients, and NGM621 for addressing dry age-related macular degeneration. Founded in 2007 and headquartered in South San Francisco, NGM Biopharmaceuticals is committed to leveraging insights from human clinical and genetic studies to develop transformative therapies, particularly focusing on the gastrointestinal endocrine system and its role in metabolic diseases. The company collaborates with Merck Sharp & Dohme Corp for research and product development initiatives.
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for rare disorders and oncology. Notably, it offers Translarna and Emflaza for treating nonsense mutation Duchenne muscular dystrophy in ambulatory patients. The company is advancing several clinical programs, including Translarna for nonsense mutation aniridia and Dravet syndrome/CDKL5, as well as RG7916 and RO7034067 for spinal muscular atrophy. Additionally, PTC Therapeutics is developing PTC596 and PTC299, a small molecule targeting cancer treatment, and a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. Collaborations with various organizations, including F. Hoffman-La Roche and the Spinal Muscular Atrophy Foundation, enhance its research and commercialization efforts. Founded in 1998, PTC Therapeutics is headquartered in South Plainfield, New Jersey.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases such as liver disease NASH and specific cancers, with a focus on targeting dysfunctional metabolic pathways. It was founded in 2007 and headquartered in San Mateo, California.
Aragon Pharmaceuticals is a discovery-stage small molecule company dedicated to developing therapeutics for hormone-resistant cancers, particularly focusing on prostate and breast cancer. The company specializes in anti-endocrine therapies that target the biology of these cancers. Its research emphasizes nuclear receptor biology, medicinal chemistry, and drug discovery, with the goal of identifying and developing selective androgen receptor degraders for prostate cancer and selective estrogen receptor degraders for estrogen-sensitive breast cancer.
Igenica, Inc. is a biotherapeutic company based in Burlingame, California, specializing in the discovery and development of antibodies and antibody-drug conjugates for cancer treatment. The company is dedicated to advancing immunotherapies and functional antibodies that target tumors, as well as creating antibody-drug conjugates. Igenica's key products include IGN523, a humanized monoclonal antibody aimed at various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, which targets immune checkpoints in the tumor microenvironment. Founded in 2008, Igenica operates with a strategic oncology research agreement with MedImmune and is backed by prominent life science investors. The leadership team at Igenica has significant experience in antibody drug discovery and has contributed to the development of multiple approved antibody therapeutic products.
Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.